Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Shares of Vertex Pharmaceuticals Inc. VRTX rallied 1.70% to $511.74 Monday, on what proved to be an all-around great trading ...

Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of indirect tax technology solutions, reveals that while free, easy product returns are paramount for consumer loyalty, they ...

Annual Information Form for the year ended December 31, 2024, which may be accessed on Vertex's SEDAR+ profile at www.sedarplus.ca. The forward-looking statements contained in this Press Release ...

Masaki Kashiwara, this year’s Abel Prize winner, co-founded a new field of mathematics called algebraic analysis ...

Have you ever wondered why walking from point A to B can be easy in some places, and incredibly frustrating in others? Well, ...

It also leads on math (AIME 2025), and science (GPQA diamond ... is rolling out first to Gemini Advanced and Google AI Studio, with Vertex AI following in the coming weeks. We’ll also introduce ...

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...